Adrenocortical carcinoma laboratory findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Ahmed Younes (talk | contribs) |
||
| (13 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Adrenocortical carcinoma}} | {{Adrenocortical carcinoma}} | ||
{{CMG}} {{AE}} {{AAM}} | {{CMG}}; {{AE}} {{AAM}} {{MAD}} | ||
==Overview== | ==Overview== | ||
Patients with functional adrenocortical carcinoma may have elevated concentrations of [[serum]] [[cortisol]], [[aldosterone]], [[testosterone]] or [[estrogen]] and reduced concentration of plasma [[renin]] and [[potassium]]. | |||
==Laboratory Findings== | ==Laboratory Findings== | ||
Laboratory findings | Laboratory findings consistent with adrenocortical carcinoma are: | ||
* | |||
* | {| class="wikitable" | ||
* | !Hormonal disturbance | ||
* | !labs | ||
* | |- | ||
* | | '''Cortisol'''<ref name="pmid3838451">{{cite journal| author=Dunlap NE, Grizzle WE, Siegel AL| title=Cushing's syndrome. Screening methods in hospitalized patients. | journal=Arch Pathol Lab Med | year= 1985 | volume= 109 | issue= 3 | pages= 222-9 | pmid=3838451 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3838451 }}</ref> | ||
* | | | ||
*[[Cortisol level]] | |||
*[[Adrenocorticotropic hormone|ACTH]] (10 pg/mL) | |||
*24-hour urinary free cortisol | |||
*Fasting serum [[cortisol]] at 8 AM following a 1 mg dose of [[dexamethasone]] at bedtime | |||
|- | |||
|'''Steroids'''<ref name="pmid19500769">{{cite journal| author=Fassnacht M, Allolio B| title=Clinical management of adrenocortical carcinoma. | journal=Best Pract Res Clin Endocrinol Metab | year= 2009 | volume= 23 | issue= 2 | pages= 273-89 | pmid=19500769 | doi=10.1016/j.beem.2008.10.008 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19500769 }}</ref> | |||
| | |||
* [[Androgen|Adrenal androgens]] ([[DHEAS]]) | |||
* [[Androstenedione]] | |||
* Bioavailable [[testosterone]] should be measured in every patient. | |||
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | |||
* Serum [[estradiol]] in men and [[postmenopausal]] women | |||
* A recent study has shown significant differences in [[steroid hormones]] precursor and metabolite profiles in the urine of patients with ACC compared to patients with [[Adrenocortical adenoma|benign adrenal tumors]]. | |||
|- | |||
|'''Epinephrine'''<ref name="pmid21385478">{{cite journal| author=Song G, Joe BN, Yeh BM, Meng MV, Westphalen AC, Coakley FV| title=Risk of catecholamine crisis in patients undergoing resection of unsuspected pheochromocytoma. | journal=Int Braz J Urol | year= 2011 | volume= 37 | issue= 1 | pages= 35-40;discussion 40-1 | pmid=21385478 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21385478 }}</ref> | |||
| | |||
* [[Metanephrine]] and [[normetanephrine]] in the plasma or 24-hour urine | |||
|- | |||
|'''Aldosterone'''<ref name="pmid21917861">{{cite journal| author=Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA et al.| title=Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. | journal=J Clin Endocrinol Metab | year= 2011 | volume= 96 | issue= 12 | pages= 3775-84 | pmid=21917861 | doi=10.1210/jc.2011-1565 | pmc=3232629 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21917861 }}</ref> | |||
| | |||
* Low serum [[aldosterone]] concentrations, normal or high serum or urinary concentrations of [[aldosterone]] precursors | |||
|} | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
| Line 18: | Line 41: | ||
{{WS}} | {{WS}} | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
Latest revision as of 16:43, 19 October 2017
|
Adrenocortical carcinoma Microchapters |
|
Differentiating Adrenocortical carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Study |
|
Adrenocortical carcinoma laboratory findings On the Web |
|
American Roentgen Ray Society Images of Adrenocortical carcinoma laboratory findings |
|
Risk calculators and risk factors for Adrenocortical carcinoma laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]
Overview
Patients with functional adrenocortical carcinoma may have elevated concentrations of serum cortisol, aldosterone, testosterone or estrogen and reduced concentration of plasma renin and potassium.
Laboratory Findings
Laboratory findings consistent with adrenocortical carcinoma are:
| Hormonal disturbance | labs |
|---|---|
| Cortisol[1] |
|
| Steroids[2] |
|
| Epinephrine[3] |
|
| Aldosterone[4] |
|
References
- ↑ Dunlap NE, Grizzle WE, Siegel AL (1985). "Cushing's syndrome. Screening methods in hospitalized patients". Arch Pathol Lab Med. 109 (3): 222–9. PMID 3838451.
- ↑ Fassnacht M, Allolio B (2009). "Clinical management of adrenocortical carcinoma". Best Pract Res Clin Endocrinol Metab. 23 (2): 273–89. doi:10.1016/j.beem.2008.10.008. PMID 19500769.
- ↑ Song G, Joe BN, Yeh BM, Meng MV, Westphalen AC, Coakley FV (2011). "Risk of catecholamine crisis in patients undergoing resection of unsuspected pheochromocytoma". Int Braz J Urol. 37 (1): 35–40, discussion 40-1. PMID 21385478.
- ↑ Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA; et al. (2011). "Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors". J Clin Endocrinol Metab. 96 (12): 3775–84. doi:10.1210/jc.2011-1565. PMC 3232629. PMID 21917861.